Plain-English translation of NCT06162221 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing several new medications called RAS inhibitors — specifically , , and — to see if they work better when combined with standard cancer treatments like or chemotherapy. The study focuses on advanced lung cancer patients whose tumors have specific genetic mutations (KRAS G12C, RAS mutations, or RAS G12D). Researchers want to find the right doses and combinations to help treat this type of cancer.
Current treatments don't work well enough for all patients with these specific genetic mutations in their lung cancer. This trial is testing whether the new medication can be more effective, especially when combined with existing approved cancer treatments.
You likely qualify if…
You likely don't qualify if…
You would visit the research center regularly to receive the medication — either as a daily pill or twice daily, depending on which part of the study you join — along with standard cancer treatments like infusions or chemotherapy. The study has different phases: first, doctors find the right dose for you, then you may continue in an expansion phase where more patients receive that dose to confirm it works. Throughout the trial, you'll have blood tests, imaging scans, and checkups to monitor how the treatment is working and any side effects.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States